Moderna stock rallies after FDA OKs booster shot of COVID-19 vaccine for most at-risk adults

Shares of Moderna Inc. ran up 3.4% in premarket trading Friday, after the Food and Drug Administration authorized a third shot of COVID-19 vaccines from Moderna and Pfizer-BioNTech for immunocompromised adults. The booster shot will be for people who have undergone organ transplants, who are undergoing chemotherapy and those taking chronic medications that can suppress immune systems. "We recognize the need to protect immunocompromised individuals who are at the highest risk of severe COVID-19 disease," said Moderna Chief Executive Stéphane Bancel. "It is promising to see recent studies demonstrating that a third dose of the Moderna COVID-19 vaccine may enhance immune response in immunocompromised populations." The company said a double-blind, randomized controlled trial of 120 people who had undergone solid organ transplants showed that a third dose of Moderna's COVID-19 vaccine improved immune response compared with placebo, and was generally well tolerated. Moderna's early stock rally comes as Pfizer Inc. shares rose 0.7% and BioNTech SE's stock climbed 3.6%, while futures for the S&P 500 gained 0.1%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Moderna stock rallies after FDA OKs booster shot of COVID-19 vaccine for most at-risk adults
Shares of Moderna Inc. ran up 3.4% in premarket trading Friday, after the Food and Drug Administration authorized a third shot of COVID-19 vaccines from Moderna and Pfizer-BioNTech for immunocompromised adults. The booster shot will be for people who have undergone organ transplants, who are undergoing chemotherapy and those taking chronic medications that can suppress immune systems. "We recognize the need to protect immunocompromised individuals who are at the highest risk of severe COVID-19 disease," said Moderna Chief Executive Stéphane Bancel. "It is promising to see recent studies demonstrating that a third dose of the Moderna COVID-19 vaccine may enhance immune response in immunocompromised populations." The company said a double-blind, randomized controlled trial of 120 people who had undergone solid organ transplants showed that a third dose of Moderna's COVID-19 vaccine improved immune response compared with placebo, and was generally well tolerated. Moderna's early stock rally comes as Pfizer Inc. shares rose 0.7% and BioNTech SE's stock climbed 3.6%, while futures for the S&P 500 gained 0.1%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.